Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to RMB 7.7 billion (USD 1.1 billion). Innovative drug business surged 27.9% to RMB 6.304 billion (USD 913 million), driving profits attributable to shareholders up 86.2% to RMB 1.344 billion (USD 194 million). The company launched two new innovative products – Quviviq (daridorexan) for insomnia and Enzeshu (suvemcitug) for platinum-resistant ovarian cancer – expanding its neuroscience and oncology franchises.
Stable cash flow – established RA/lupus positioning
Other
RMB 1.099B
-18.7%
Legacy products
Portfolio optimization – divestment of non-core assets
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026 revenue growth, Quviviq/Enzeshu market penetration, and therapeutic area expansion. Actual results may differ due to competitive dynamics in insomnia (lemborexant, daridorexan) and ovarian cancer (PARP inhibitors, bevacizumab), and NRDL negotiation outcomes for new products.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
